Chikezie Alvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chikezie Alvarez has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Dirweesh
Department of Internal Medicine, Seton Hall University School of Medicine, Saint Francis Medical Center, Trenton, NJ, USA
6 shared publications Sandeep Aggarwal
Nephrology, University of Pennsylvania, Philadelphia, USA
5 shared publicationsHoward Eisen
Penn State Hershey Heart and Vascular Institute, Hershey, PA, USA
4 shared publicationsMuhammad Khan
Department of Internal Medicine, Seton Hall University School of Medicine, Saint Francis Medical Center, Trenton, NJ, USA
4 shared publicationsDonald Christmas
Internal Medicine, Hackensack Meridian School of Medicine at Seton Hall University, Nutley, USA
3 shared publicationsJeffrey Kluger
Division of Cardiology Hartford Hospital Hartford Connecticut USA
3 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (4) , e014151
Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall
BACKGROUND: Although emerging evidence supports 3-dimensional myocardial activation during atrial fibrillation (AF), human studies remain limited. We thus characterized the endocardial and epicardial left atrial posterior wall (LAPW) in humans to assess the prevalence of asynchronous endocardial-epicardial LAPW conduction during AF. METHODS: Patients with symptomatic nonparoxysmal AF who had unsuccessful antiarrhythmic or catheter ablation therapy referred for hybrid epicardial-endocardial AF ablation and left atrial appendage ligation underwent high-density mapping of LAPW with Grid catheters, including simultaneous endocardial-epicardial mapping. RESULTS: Twenty-seven patients (19 men, median 69 years, 55% long-standing persistent AF) were included. There was significantly greater epicardial compared with endocardial LAPW bipolar voltages during AF. In areas of low endocardial bipolar voltage, normal endocardial unipolar voltage corresponded to normal epicardial bipolar voltage. Asynchronous endocardial-epicardial LAPW AF activation during simultaneous endocardial-epicardial mapping was universal. Furthermore, more rapid epicardial compared with endocardial LAPW AF activity was observed during simultaneous endocardial-epicardial mapping in AF. Conduction block between the endocardial and epicardial LAPW surfaces was also common during organized AF, with instances of isolated or multiple blocked beats, Wenckebach conduction, and sustained endocardial LAPW entrance block with ongoing epicardial AF observed. Epicardial-to-endocardial entrance block was also infrequently observed during sinus rhythm. At 12-month follow-up, freedom from atrial arrhythmias was 68%. CONCLUSIONS: Endocardial-epicardial LAPW asynchrony may be observed during human persistent AF and is characterized by: (1) greater epicardial compared with endocardial bipolar voltages, (2) more frequent epicardial-to-endocardial activation gradients during AF, and (3) conduction block commonly seen between the epicardial and endocardial surfaces during AF. Although the study was predominantly descriptive in nature, the observations suggest a dynamic 3-dimensional arrhythmogenicity of the LAPW and the potential importance of the epicardial layer, with implications for ablation therapies. Future prospective studies are required to determine the significance of these findings to clinical ablation outcomes.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (4) , e014151
Open AccessEpicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall
BACKGROUND: Although emerging evidence supports 3-dimensional myocardial activation during atrial fibrillation (AF), human studies remain limited. We thus characterized the endocardial and epicardial left atrial posterior wall (LAPW) in humans to assess the prevalence of asynchronous endocardial-epicardial LAPW conduction during AF. METHODS: Patients with symptomatic nonparoxysmal AF who had unsuccessful antiarrhythmic or catheter ablation therapy referred for hybrid epicardial-endocardial AF ablation and left atrial appendage ligation underwent high-density mapping of LAPW with Grid catheters, including simultaneous endocardial-epicardial mapping. RESULTS: Twenty-seven patients (19 men, median 69 years, 55% long-standing persistent AF) were included. There was significantly greater epicardial compared with endocardial LAPW bipolar voltages during AF. In areas of low endocardial bipolar voltage, normal endocardial unipolar voltage corresponded to normal epicardial bipolar voltage. Asynchronous endocardial-epicardial LAPW AF activation during simultaneous endocardial-epicardial mapping was universal. Furthermore, more rapid epicardial compared with endocardial LAPW AF activity was observed during simultaneous endocardial-epicardial mapping in AF. Conduction block between the endocardial and epicardial LAPW surfaces was also common during organized AF, with instances of isolated or multiple blocked beats, Wenckebach conduction, and sustained endocardial LAPW entrance block with ongoing epicardial AF observed. Epicardial-to-endocardial entrance block was also infrequently observed during sinus rhythm. At 12-month follow-up, freedom from atrial arrhythmias was 68%. CONCLUSIONS: Endocardial-epicardial LAPW asynchrony may be observed during human persistent AF and is characterized by: (1) greater epicardial compared with endocardial bipolar voltages, (2) more frequent epicardial-to-endocardial activation gradients during AF, and (3) conduction block commonly seen between the epicardial and endocardial surfaces during AF. Although the study was predominantly descriptive in nature, the observations suggest a dynamic 3-dimensional arrhythmogenicity of the LAPW and the potential importance of the epicardial layer, with implications for ablation therapies. Future prospective studies are required to determine the significance of these findings to clinical ablation outcomes.
- Open Access
- 20 August 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (9) , 101210
Atrial Fibrillation in Hypertrophic Cardiomyopathy
- 20 August 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (9) , 101210
Open AccessAtrial Fibrillation in Hypertrophic Cardiomyopathy
- 5 June 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (7) , 1515-1522
Erroneous electrocardiographic interpretations and its clinical implications
Introduction: The advancement of artificial intelligence (AI) has aided clinicians in the interpretation of electrocardiograms (ECGs) serving as an essential tool to provide rapid triage and care. However, in some cases, AI can misinterpret an ECG and may mislead the interpreting physician. Therefore, we aimed to describe the rate of ECG misinterpretation and its potential clinical impact in patient's management.Methods: We performed a retrospective descriptive analysis of misinterpreted ECGs and its clinical impact from May 28, 2020 to May 9, 2021. An electrophysiologist screened ECGs with confirmed diagnosis of atrial fibrillation (AF), sinus tachycardia (ST), sinus bradycardia (SB), intraventricular conduction delay (IVCD), and premature atrial contraction (PAC) that were performed in the emergency department. We then classified the misinterpreted ECGs as wrongly diagnosed AF, ST, SB, IVCD, or PAC into the correct diagnosis and reviewed the misinterpreted ECGs and medical records to evaluate inappropriate use of antiarrhythmic drugs (AAD), beta‐blockers (BB), calcium channel blockers (CCB), anticoagulation, or resource utilization of cardiology and/or electrophysiology (EP) consultation.Results: A total of 4969 ECGs were screened with diagnoses of AF (2282), IVCD (296), PAC (972), SB (895), and ST (638). Among these, 101 ECGs (2.0%) were misinterpreted. Wrongly diagnosed AF (58.4%) was the most common followed by wrongly diagnosed PAC (14.9%), wrongly diagnosed ST (12.9%), wrongly diagnosed IVCD (7.9%), and wrongly diagnosed SB (6.0%). Patients with misinterpreted ECGs were aged 76.6 ± 11.6 years with male (52.5%) predominance and hypertension being the most prevalent (83.2%) comorbid condition. The misinterpretation of ECGs led to the inappropriate use of BB (19.8%), CCB (5.0%), AAD therapy (7.9%), anticoagulation (6.9%) in patients with wrongly diagnosed AF, as well as inappropriate resource utilization including cardiology (41.6%) and EP (8.9%) consultations.Conclusions: Misinterpretation of ECGs may lead to inappropriate medical therapies and increased resource utilization. Therefore, it is essential to encourage physicians to carefully examine AI interpreted ECG's, especially those interpreted as having AF.
- 5 June 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (7) , 1515-1522
Erroneous electrocardiographic interpretations and its clinical implications
Introduction: The advancement of artificial intelligence (AI) has aided clinicians in the interpretation of electrocardiograms (ECGs) serving as an essential tool to provide rapid triage and care. However, in some cases, AI can misinterpret an ECG and may mislead the interpreting physician. Therefore, we aimed to describe the rate of ECG misinterpretation and its potential clinical impact in patient's management.Methods: We performed a retrospective descriptive analysis of misinterpreted ECGs and its clinical impact from May 28, 2020 to May 9, 2021. An electrophysiologist screened ECGs with confirmed diagnosis of atrial fibrillation (AF), sinus tachycardia (ST), sinus bradycardia (SB), intraventricular conduction delay (IVCD), and premature atrial contraction (PAC) that were performed in the emergency department. We then classified the misinterpreted ECGs as wrongly diagnosed AF, ST, SB, IVCD, or PAC into the correct diagnosis and reviewed the misinterpreted ECGs and medical records to evaluate inappropriate use of antiarrhythmic drugs (AAD), beta‐blockers (BB), calcium channel blockers (CCB), anticoagulation, or resource utilization of cardiology and/or electrophysiology (EP) consultation.Results: A total of 4969 ECGs were screened with diagnoses of AF (2282), IVCD (296), PAC (972), SB (895), and ST (638). Among these, 101 ECGs (2.0%) were misinterpreted. Wrongly diagnosed AF (58.4%) was the most common followed by wrongly diagnosed PAC (14.9%), wrongly diagnosed ST (12.9%), wrongly diagnosed IVCD (7.9%), and wrongly diagnosed SB (6.0%). Patients with misinterpreted ECGs were aged 76.6 ± 11.6 years with male (52.5%) predominance and hypertension being the most prevalent (83.2%) comorbid condition. The misinterpretation of ECGs led to the inappropriate use of BB (19.8%), CCB (5.0%), AAD therapy (7.9%), anticoagulation (6.9%) in patients with wrongly diagnosed AF, as well as inappropriate resource utilization including cardiology (41.6%) and EP (8.9%) consultations.Conclusions: Misinterpretation of ECGs may lead to inappropriate medical therapies and increased resource utilization. Therefore, it is essential to encourage physicians to carefully examine AI interpreted ECG's, especially those interpreted as having AF.
- 21 October 2022
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 37 (1) , 96-111
Anesthetic Considerations in the Electrophysiology Laboratory: A Comprehensive Review
- 21 October 2022
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 37 (1) , 96-111
Anesthetic Considerations in the Electrophysiology Laboratory: A Comprehensive Review
- Open Access
- 16 December 2021
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 8 (3) , 200-204
Dual myosin binding protein C3 and potassium voltage-gated channel subfamily H member 2 co-inherited pathogenic variants in a patient with hypertrophic cardiomyopathy and long QT 2 syndrome: A case report
- 16 December 2021
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 8 (3) , 200-204
Open AccessDual myosin binding protein C3 and potassium voltage-gated channel subfamily H member 2 co-inherited pathogenic variants in a patient with hypertrophic cardiomyopathy and long QT 2 syndrome: A case report
- Open Access
- 28 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (12) , ytab430
A case report of deglutition triggered atrial fibrillation in a patient with Laing distal myopathy
Background: Deglutition-induced atrial fibrillation is a rare clinical entity with a reported prevalence of 0.6%. Laing distal myopathy is a rare autosomal dominant muscular dystrophy that is the result of mutations within the slow skeletal muscle fibre myosin heavy chain gene (MYH7). Atrial fibrillation has not been previously reported in patients with Laing distal myopathy. We describe the first reported case of deglutition triggered atrial fibrillation in a female with a history of Laing distal myopathy.Case summary: A 44-year-old female with a history of Laing distal myopathy diagnosed at age 32, began experiencing intermittent episodes of pre-syncope and palpitations which occurred after deglutition with food. An ambulatory 30-day patient triggered event monitor recorded episodes of atrial fibrillation with rapid ventricular response. Family history was significant for Laing distal myopathy, atrial fibrillation, as well as sudden cardiac death. Laboratory data, transthoracic echocardiogram, cardiac magnetic resonance imaging, and an exercise treadmill SPECT Imaging stress test were normal. An oesophagram revealed a mild oesophageal dysmotility with no other abnormalities. She was started on flecainide 50 mg p.o. every 8 h and verapamil 40 mg p.o. every 8 h with no further episodes of atrial fibrillation.Discussion: Given the strong genetic component of this myopathy, one could postulate as to a possible genetic component in the development of atrial fibrillation in our patient. Although we cannot make definite correlation between deglutition-induced atrial fibrillation and Laing myopathy, it is important to report this unusual association which has not been described before.
- 28 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (12) , ytab430
Open AccessA case report of deglutition triggered atrial fibrillation in a patient with Laing distal myopathy
Background: Deglutition-induced atrial fibrillation is a rare clinical entity with a reported prevalence of 0.6%. Laing distal myopathy is a rare autosomal dominant muscular dystrophy that is the result of mutations within the slow skeletal muscle fibre myosin heavy chain gene (MYH7). Atrial fibrillation has not been previously reported in patients with Laing distal myopathy. We describe the first reported case of deglutition triggered atrial fibrillation in a female with a history of Laing distal myopathy.Case summary: A 44-year-old female with a history of Laing distal myopathy diagnosed at age 32, began experiencing intermittent episodes of pre-syncope and palpitations which occurred after deglutition with food. An ambulatory 30-day patient triggered event monitor recorded episodes of atrial fibrillation with rapid ventricular response. Family history was significant for Laing distal myopathy, atrial fibrillation, as well as sudden cardiac death. Laboratory data, transthoracic echocardiogram, cardiac magnetic resonance imaging, and an exercise treadmill SPECT Imaging stress test were normal. An oesophagram revealed a mild oesophageal dysmotility with no other abnormalities. She was started on flecainide 50 mg p.o. every 8 h and verapamil 40 mg p.o. every 8 h with no further episodes of atrial fibrillation.Discussion: Given the strong genetic component of this myopathy, one could postulate as to a possible genetic component in the development of atrial fibrillation in our patient. Although we cannot make definite correlation between deglutition-induced atrial fibrillation and Laing myopathy, it is important to report this unusual association which has not been described before.
- Open Access
- 15 December 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (24) , e018475
Statin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19
Background: Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19. Methods and Results: An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years; P P P P =0.82). Propensity score matching (hazard ratio, 0.88; 95% CI, 0.83–0.94; P P <0.01) showed a 12% lower risk of death during hospitalization for statin users than for nonusers. Conclusions: Statin use was associated with reduced in‐hospital mortality from COVID‐19 in patients with diabetes mellitus. These findings, if validated, may further reemphasize administration of statins to patients with diabetes mellitus during the COVID‐19 era.
- 15 December 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (24) , e018475
Open AccessStatin Use and In‐Hospital Mortality in Patients With Diabetes Mellitus and COVID‐19
Background: Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19. Methods and Results: An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years; P P P P =0.82). Propensity score matching (hazard ratio, 0.88; 95% CI, 0.83–0.94; P P <0.01) showed a 12% lower risk of death during hospitalization for statin users than for nonusers. Conclusions: Statin use was associated with reduced in‐hospital mortality from COVID‐19 in patients with diabetes mellitus. These findings, if validated, may further reemphasize administration of statins to patients with diabetes mellitus during the COVID‐19 era.
- Open Access
- 26 September 2020
- Published by Springer Nature in Cureus
- Vol. 12 (9) , e10673
Significant Difference in Acute Coronary Lesions in Patients on Therapeutic Statin Therapy Compared to Those Without
Statin therapy has been shown to alter coronary plaque via decreasing lipid-rich pools, substituting with fibrocalcific plaque. We propose that acute coronary lesions in patients on therapeutic statin therapy, compared with patients not on statin therapy with elevated low-density lipoprotein (LDL) levels, will have features typically not associated with lipid-rich disease, such as lengthy fibrocalcific lesions, stent failure (in-stent restenosis and stent thrombosis), and/or bypass graft degeneration. Charts and coronary angiograms of 143 consecutive patients from May 2016 to December 2018 with Type 1 Myocardial Infarction Fourth Universal Definition were retrospectively reviewed. Patients were divided into two groups: group 1, those on statin therapy with an LDL < 100 mg/dL, and group 2, those not on statin therapy with an LDL ≥ 100 mg/dL at the time of an acute coronary syndrome. Acute lesion characteristics and angioplasty techniques/equipment were recorded. There were 56 patients in group 1 and 39 patients in group 2. Group 1 patients, compared with group 2, were more likely to have moderate-severe vessel calcification (55.4% vs 10.3%; p < 0.01), lesion length greater than 20 mm (51.8% vs 23.1%; p = 0.019), stent failure (39.3% vs 7.7%; p < 0.01), and bypass graft failure (23.2% vs 7.7%; p = 0.04). Coronary interventions in group 1, compared with group 2, more often required adjunctive angioplasty techniques, including the need for multiple coronary wires, guide extender, thrombectomy, and circulatory support (51.8% vs 7.7%; p < 0.01). There was no significant difference between the number of culprit vessels, including the specific coronary culprit vessel identified between both groups. Acute coronary lesions in patients on therapeutic statin therapy, compared to those not on statin therapy with an elevated LDL, tend to be longer, more calcific with increased vessel tortuosity and angulation, as well as from a stent or bypass graft failure mechanism. Furthermore, there is a signal for heightened procedural complexity in the arm with statin therapy. These clinical findings are likely the result of the altered natural history of plaque pathophysiology seen with statin therapy.
- 26 September 2020
- Published by Springer Nature in Cureus
- Vol. 12 (9) , e10673
Open AccessSignificant Difference in Acute Coronary Lesions in Patients on Therapeutic Statin Therapy Compared to Those Without
Statin therapy has been shown to alter coronary plaque via decreasing lipid-rich pools, substituting with fibrocalcific plaque. We propose that acute coronary lesions in patients on therapeutic statin therapy, compared with patients not on statin therapy with elevated low-density lipoprotein (LDL) levels, will have features typically not associated with lipid-rich disease, such as lengthy fibrocalcific lesions, stent failure (in-stent restenosis and stent thrombosis), and/or bypass graft degeneration. Charts and coronary angiograms of 143 consecutive patients from May 2016 to December 2018 with Type 1 Myocardial Infarction Fourth Universal Definition were retrospectively reviewed. Patients were divided into two groups: group 1, those on statin therapy with an LDL < 100 mg/dL, and group 2, those not on statin therapy with an LDL ≥ 100 mg/dL at the time of an acute coronary syndrome. Acute lesion characteristics and angioplasty techniques/equipment were recorded. There were 56 patients in group 1 and 39 patients in group 2. Group 1 patients, compared with group 2, were more likely to have moderate-severe vessel calcification (55.4% vs 10.3%; p < 0.01), lesion length greater than 20 mm (51.8% vs 23.1%; p = 0.019), stent failure (39.3% vs 7.7%; p < 0.01), and bypass graft failure (23.2% vs 7.7%; p = 0.04). Coronary interventions in group 1, compared with group 2, more often required adjunctive angioplasty techniques, including the need for multiple coronary wires, guide extender, thrombectomy, and circulatory support (51.8% vs 7.7%; p < 0.01). There was no significant difference between the number of culprit vessels, including the specific coronary culprit vessel identified between both groups. Acute coronary lesions in patients on therapeutic statin therapy, compared to those not on statin therapy with an elevated LDL, tend to be longer, more calcific with increased vessel tortuosity and angulation, as well as from a stent or bypass graft failure mechanism. Furthermore, there is a signal for heightened procedural complexity in the arm with statin therapy. These clinical findings are likely the result of the altered natural history of plaque pathophysiology seen with statin therapy.
- 1 May 2020
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 13 (5) , e007017
Axillary Intra-Aortic Balloon Pump Migration Into the Left Ventricle During Peripheral Venoarterial Extracorporeal Membrane Oxygenation Support
- 1 May 2020
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 13 (5) , e007017
Axillary Intra-Aortic Balloon Pump Migration Into the Left Ventricle During Peripheral Venoarterial Extracorporeal Membrane Oxygenation Support